Graphical Review

Redox-dependent regulation of epidermal growth factor receptor signaling

David E. Heppner, Albert van der Vliet*

Department of Pathology and Laboratory Medicine, Vermont Lung Center, University of Vermont, Burlington, VT 05405, United States

Abstract

Tyrosine phosphorylation-dependent cell signaling represents a unique feature of multicellular organisms, and is important in regulation of cell differentiation and specialized cell functions. Multicellular organisms also contain a diverse family of NADPH oxidases (NOXs) that have been closely linked with tyrosine kinase-based cell signaling and regulate tyrosine phosphorylation via reversible oxidation of cysteine residues that are highly conserved within many proteins involved in this signaling pathway. An example of redox-regulated tyrosine kinase signaling involves the epidermal growth factor receptor (EGFR), a widely studied receptor system with diverse functions in normal cell biology as well as pathologies associated with oxidative stress such as cancer. The purpose of this Graphical Redox Review is to highlight recently emerged concepts with respect to NOX-dependent regulation of this important signaling pathway.

© 2015 Elsevier B.V. Published by Elsevier B.V. All rights reserved.

1. Introduction

The epidermal growth factor receptor (EGFR) is a member of the extensively studied ErbB receptor tyrosine kinase family that plays important roles in cell growth, development, differentiation, cytoskeletal organization, and cell migration. The EGFR and other ErbB members are activated by a family of ligands which promote receptor homo- or heterodimerization resulting in autophosphorylation of intracellular tyrosine residues, thereby recruiting various adapter molecules and activating an array of downstream signaling cascades [1]. In addition to this canonical activation mechanism, EGFR is also frequently activated in a cross-talk mechanism by initial stimulation of G-protein coupled receptors (GPCRs), a large receptor family for diverse stimuli including proteins, peptides, lipids, amino acids, biogenic amines, and ions. Such EGFR transactivation occurs by two interrelated mechanisms, the first involving a “triple-membrane-passing-signal” in which GPCR activation leads to activation of membrane-bound matrix metalloproteases (MMPs) such as the ADAM (a disintegrin and metalloprotease) family, which subsequently promotes shedding of membrane-anchored EGFR ligands, allowing them to bind to ErbB receptors [2]. In addition, GPCR-dependent EGFR activation also involves ligand-independent mechanisms that result in direct EGFR phosphorylation and activation, which is mediated by intermediate activation of protein kinases that include the non-receptor Src family kinases (SFK) or protein tyrosine kinase 2 (Pyk2) (Fig. 1).

*Correspondence to: Department of Pathology and Laboratory Medicine, University of Vermont, HRSF Building, Room 216, 149 Beaumont Avenue, Burlington, VT 05405, United States.
E-mail address: albert.van-der-vliet@uvm.edu (A. van der Vliet).

http://dx.doi.org/10.1016/j.redox.2015.12.002
2213-2317/© 2015 Elsevier B.V. Published by Elsevier B.V. All rights reserved.
2. Redox control of tyrosine kinase signaling

Tyrosine kinase-based signaling, including EGFR, is well-known to be subject to regulation by redox-dependent mechanisms at various levels [3] (Fig. 2). The coincidence of tyrosine phosphorylation as an important signaling mechanism in multicellular organisms with increased diversity in NADPH oxidase (NOX) isoforms, the major source of regulated ROS production, in these more complex organisms suggests an intricate relationship in the evolution of these systems [4,5]. Pioneering studies by Rhee and co-workers illustrated that activation of EGFR is associated with ROS production, which transiently inactivates protein tyrosine phosphatases (PTPs) to enhance or prolong EGFR activation [6]. Such redox-mediated PTP inactivation is due to oxidation of a susceptible conserved catalytic cysteine residue that is essential for phosphotyrosine hydrolysis [7]. More recent studies highlighted the importance of regulated ROS production by NOX family NADPH oxidases in site-specific PTP inactivation in spatially confined areas, e.g. by NOX4 in the ER [8] or NOX2 at sites of focal adhesion [9]. Indeed, such NOX-dependent PTP inactivation is now well appreciated in promoting EGFR-dependent signaling (Fig. 3A).

In addition to the well-documented negative regulation of PTPs by oxidative mechanisms, evidence is emerging that protein tyrosine kinases are also subject to more direct redox regulation [10]. This is best studied in the SFK family, which contain a number of conserved cysteines, whose oxidation either promotes or restricts kinase activity.

**Fig. 1.** Direct and indirect mechanisms of EGFR activation. Activation of EGFR by cognate ligands results in homo- or heterodimerization and autophosphorylation of intracellular tyrosine residues (e.g., Y1068) to initiate cellular signaling. EGFR is commonly activated indirectly by activation of GPCR (transactivation), which involves intermediate activation of protein kinases such as SFK, resulting in MMP/ADAM-dependent EGFR ligand shedding as well as direct phosphorylation of EGFR (Y845) to promote EGFR kinase activation.

**Fig. 2.** Interrelationships between NOX/DUOX enzymes and protein tyrosine phosphorylation. Regulated activation of NOX/DUOX controls tyrosine phosphorylation by reversible oxidative modification of conserved cysteine residues with protein tyrosine phosphatases (resulting in inactivation) or in protein tyrosine kinases such as Src family kinases (SFK) or EGFR (which often enhances kinase activity).

**Fig. 3.** Diverse modes of NOX-dependent regulation of EGFR activation. (A) Ligand-induced EGFR activation is associated with transient cysteine oxidation (-S-Ox) within PTP1B through intermediate NOX activation (e.g. NOX2 or NOX4), resulting in its inactivation and relieving its inhibitory action of EGFR tyrosine phosphorylation and activation. (B) Ligand-induced EGFR activation results in NOX2-dependent oxidation of a conserved cysteine within the EGFR kinase domain (Cys797), which is associated with enhanced kinase activity. (C) EGFR transactivation by GPCR stimulation (e.g., P2Y1R) involves NOX activation (DUOX1 or NOX1) and cysteine oxidation within Src, which promotes Src activation and subsequent MMP/ADAM-dependent EGFR ligand shedding as well as direct EGFR phosphorylation.
The precise molecular mechanisms by which these distinct oxidative events control EGFR-dependent signaling is not always clear. While it is well-appreciated that oxidation of the catalytic cysteine within PTPs results in impaired phosphatase activity, irrespective of the nature of the oxidative modification (S-nitrosylation, S-glutathionylation, sulfenyl amide formation), it is less obvious how oxidative modifications of non-catalytic cysteines in tyrosine kinases affect enzyme activity. Indeed, oxidative modification of one or more conserved cysteines in SFKs have been linked with either enhanced or reduced kinase activity, but the precise molecular mechanisms is still unclear [10,17]. Intriguingly, oxidation of Cys797 in the ATP-binding pocket of EGFR to a sulfenic acid was linked to enhanced kinase activity, potentially due to altered electrostatic or hydrogen bonding interaction with its substrate [18]. In contrast, other oxidative modifications of this Cys residue, to either S-glutathionylated adds or to sulfenic acids, do not enhance tyrosine kinase activity [11] and might in fact be inhibitory due to steric constraints imposed by more bulky modifications of this Cys residue. Indeed, Cys797 is also the target for recently developed covalent EGFR inhibitors that have been used to treat lung cancers with activating EGFR mutations [19]. Based on these considerations, we propose that reversible oxidation of Cys797, which likely involves initial sulfenic acid formation that is subsequently resolved by S-glutathionylation and reduction, represents another level of dynamic redox-dependent EGFR regulation, complementing its regulation by tyrosine phosphorylation/dephosphorylation (Fig. 4).

4. Conclusion

In conclusion, current experimental evidence indicates a tight interrelationship between NOX-dependent ROS production and redox-mediated regulation of tyrosine kinases such as EGFR. The highly diverse nature of EGFR signaling in various cellular contexts is therefore not only explained by the diversity in EGFR ligands and/or variable EGFR homo- or heterodimerization, but also by variable expression and activation of diverse NOX enzymes which can control EGFR activation at various levels and thereby regulate either initiation of EGFR transactivation or the extent of EGFR activation and its diverse downstream signaling pathways. Hence, abnormalities in EGFR activation in the context of chronic diseases such as cancer or asthma may not simply be due to altered expression of EGFR or its ligands, but also be related to altered expression or activation of NOX enzymes that regulate this signaling pathway.

Acknowledgments

The authors kindly acknowledge research support from NIH to AvdV (HL085656 and ES021476) and a T32 post-doctoral fellowship to DEH (HL076122).

References

[1] M.A. Lemmon, J. Schlessinger, K.M. Ferguson, The EGFR family: not so prototypical receptor tyrosine kinases, Cold Spring Harb. Perspect. Biol. 6 (2014) a020768.
[2] H. Ohitsu, P.J. Dempsey, S. Eguchi, ADAMs as mediators of EGFR receptor transactivation by C protein-coupled receptors, Am. J. Physiol. Cell Physiol. 291 (2006) C1–10.
[3] T. Finkel, Signal transduction by reactive oxygen species, J. Cell Biol. 194 (2011) 7–15.
[4] A. van der Vliet, NADPH oxides in lung biology and pathology: host defense enzymes, and more, Free Radic. Biol. Med. 44 (2008) 938–955.
[5] L.S. Terada, Specificity in reactive oxidant signaling: think globally, act locally, J. Cell Biol. 174 (2006) 615–623.
[6] S.R. Lee, K.S. Kwon, S.R. Kim, S.G. Rhee, Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor, J. Biol. Chem. 273 (1998) 15366–15372.
[7] N.K. Tonks, Redox redux: revisiting PTPs and the control of cell signaling, Cell 121 (2005) 667–670.
[8] K. Chen, M.T. Kirber, H. Xiao, Y. Yang, J.F. Keaney Jr., Regulation of ROS signal transduction by NADPH oxidase 4 localization, J. Cell Biol. 181 (2008) 1129–1139.
[9] R.F. Wu, et al., Subcellular targeting of oxidants during endothelial cell migration, J. Cell Biol. 171 (2005) 893–904.
[10] A. Corcoran, T.G. Cotter, Redox regulation of protein kinases, FEBS J. 280 (2013) 1944–1965.
[11] P.A. Schwartz, et al., Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance, Proc. Natl. Acad. Sci. USA 111 (2014) 173–178.
[12] C.E. Paulsen, et al., Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity, Nat. Chem. Biol. 8 (2012) 57–64.
[13] D. Sham, U.V. Wesley, M. Hristova, A. van der Vliet, ATP-mediated transactivation of the epidermal growth factor receptor in airway epithelial cells involves DUOX1-dependent oxidation of Src and ADAM17, PLoS One 8 (2013) e54391.
[14] D.K. Jagadeesha, M. Takapoo, B. Banfi, R.C. Bhalla, F.J. Miller Jr., Nox1 transactivation of epidermal growth factor receptor promotes N-cadherin shedding and smooth muscle cell migration, Cardiovasc. Res. 93 (2012) 406–413.
[15] M. Hristova, et al., Identification of DUOX1-dependent redox signaling through protein S-glutathionylation in airway epithelial cells, Redox Biol. 2 (2014) 436–446.
[16] M. Hristova, et al., Airway epithelial dual oxidase 1 mediates allergen-induced IL-33 secretion and activation of type 2 immune responses, J. Allergy Clin. Immunol. (2015)10.1016/j.jaci.2015.10.003. [Epub ahead of print].
[17] E. Giannoni, P. Chiarugi, Redox circuitries driving Src regulation, Antioxid. Redox Signal 20 (2014) 2011–2025.
[18] T.H. Truong, K.S. Carroll, Redox regulation of epidermal growth factor receptor signaling through cysteine oxidation, Biochemistry 51 (2012) 9954–9965.
[19] J. Singh, R.C. Petter, T.A. Bailie, A. Whitty, The resurgence of covalent drugs, Nat. Rev. Drug Discov. 10 (2011) 307–317.